NASDAQ:DCOY Decoy Therapeutics (DCOY) Stock Price, News & Analysis $1.06 -0.04 (-3.21%) Closing price 03:50 PM EasternExtended Trading$1.06 +0.01 (+0.47%) As of 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsSEC Filings About Decoy Therapeutics Stock (NASDAQ:DCOY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Decoy Therapeutics alerts:Sign Up Key Stats Today's Range$1.05▼$1.0950-Day Range$0.92▼$3.8552-Week Range$0.90▼$16.92Volume35,213 shsAverage Volume763,215 shsMarket Capitalization$2.52 millionP/E RatioN/ADividend YieldN/APrice Target$30.00Consensus RatingHold Company Overview Decoy Therapeutics is a biotechnology company developing messenger RNA (mRNA)-based medicines. Its technology is intended to direct the body’s cells to produce therapeutic proteins, with the goal of addressing diseases through targeted biological mechanisms. The company’s research activities focus on applying its mRNA platform to potential treatments in areas including infectious disease and oncology. Its pipeline remains centered on investigational programs, and the company’s products are subject to the development, testing and regulatory approval processes required for biotechnology therapies. Publicly available information about Decoy Therapeutics’ operating history, geographic presence and leadership is limited. Additional details may become available as the company advances its development programs and provides further corporate disclosures.AI Generated. May Contain Errors. Read More Decoy Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreDCOY MarketRank™: 2.747812459185 of 5 starsDecoy Therapeutics scored higher than 55% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingDecoy Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialDecoy Therapeutics has a consensus price target of $30.00, representing about 2,757.1% upside from its current price of $1.05.Amount of Analyst CoverageDecoy Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Decoy Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Decoy Therapeutics are expected to grow in the coming year, from ($8.96) to ($8.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Decoy Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Decoy Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDecoy Therapeutics has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.25% of the float of Decoy Therapeutics has been sold short.Short Interest Ratio / Days to CoverDecoy Therapeutics has a short interest ratio ("days to cover") of 1.82, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Decoy Therapeutics has recently increased by 2.18%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDecoy Therapeutics does not currently pay a dividend.Dividend GrowthDecoy Therapeutics does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment1.26 News SentimentDecoy Therapeutics has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Decoy Therapeutics this week, compared to 2 articles on an average week. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Decoy Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders1.50% of the stock of Decoy Therapeutics is held by insiders.Percentage Held by Institutions11.88% of the stock of Decoy Therapeutics is held by institutions.Read more about Decoy Therapeutics' insider trading history. Receive DCOY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Decoy Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DCOY Stock News HeadlinesDecoy Therapeutics Named BioTech Breakthrough’s 2026 R&D Solution of the Year for IMP³ACT PlatformNovember 10 at 9:51 AM | quiverquant.comQDecoy Therapeutics Named “R&D Solution of the Year” in 2026 BioTech Breakthrough AwardsNovember 10 at 9:47 AM | globenewswire.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 12 at 1:00 AM | Behind the Markets (Ad)Decoy Therapeutics Provides Third Quarter 2026 Business UpdateNovember 3, 2026 | globenewswire.comDecoy Therapeutics consensus price target cut by 90.00% to $3.06October 2, 2026 | msn.comDecoy Therapeutics Reports Preclinical Data For Weekly Intranasal DCOY-CoVSeptember 30, 2026 | rttnews.comDecoy Therapeutics, Inc. Reports Preclinical Pk Data Supporting Once-Weekly Intranasal Administration for Dcoy-CovSeptember 30, 2026 | marketscreener.comMDecoy Therapeutics to Present at The Small Cap ShowcaseSeptember 30, 2026 | globenewswire.comSee More Headlines DCOY Stock Analysis - Frequently Asked Questions How have DCOY shares performed this year? Decoy Therapeutics' stock was trading at $9.36 on January 23, 2026. Since then, DCOY shares have decreased by 88.8% and is now trading at $1.05. How were Decoy Therapeutics' earnings last quarter? Decoy Therapeutics (NASDAQ:DCOY) announced its earnings results on Thursday, November, 12th. The company reported ($3.53) earnings per share for the quarter. The firm had revenue of $307.43 thousand for the quarter. When did Decoy Therapeutics' stock split? Shares of Decoy Therapeutics reverse split before market open on Monday, March 9th 2026.The 1-12 reverse split was announced on Thursday, March 5th 2026. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 6th 2026. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Decoy Therapeutics? Shares of DCOY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/12/2026Today11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 DCOY's financial health is in the Yellow zone, according to TradeSmith. DCOY has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:DCOY CIK1615219 Webwww.decoytx.com Phone(346) 772-0346FaxN/AEmployees11Year FoundedN/APrice Target and Rating Average Price Target for Decoy Therapeutics$30.00 High Price Target$30.00 Low Price Target$30.00 Potential Upside/Downside+2,743.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($30.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.52 million Net MarginsN/A Pretax Margin-6,337.28% Return on Equity-315.22% Return on Assets-167.15% Debt Debt-to-Equity RatioN/A Current Ratio1.83 Quick Ratio1.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.07 per share Price / Book0.10Miscellaneous Outstanding Shares2,385,000Free Float2,349,000Market Cap$2.52 million OptionableN/A Beta0.76 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:DCOY) was last updated on 11/12/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredElon wants to move AI off the planet. Amazon isn't ready.What if the next AI race isn't on Earth? Tim Bohen's Mission X presentation explores Elon Musk's idea of movin...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Decoy Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Decoy Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
